ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising new combo may halt Estrogen-Fueled breast tumors
Disease control Recruiting nowThis study tests whether a daily pill (Z-endoxifen) plus a monthly shot (goserelin) can slow or stop tumor growth in premenopausal women with ER+/HER2- breast cancer. About 87 participants will take the combination for up to 24 weeks before surgery. The main goal is to see if the…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Atossa Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 02:18 UTC
-
New combo aims to outsmart drug-resistant breast cancer
Disease control Recruiting nowThis study is for people with a common type of advanced breast cancer (ER+/HER2-) that has stopped responding to a previous targeted treatment. It compares taking the hormone drug elacestrant alone versus combining it with another targeted drug (palbociclib, abemaciclib, or riboc…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
Can a second round of radiation safely treat breast cancer recurrence?
Disease control Recruiting nowThis study is for women with a certain type of breast cancer (ER+HER2-) who have already had radiation once and now need a second lumpectomy. Researchers want to see if giving radiation again is safe and helps prevent the cancer from coming back. About 114 participants will be fo…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: NA • Sponsor: Youssef Zeidan • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New combo aims to outsmart resistant breast cancer
Disease control Recruiting nowThis study tests whether adding elacestrant to standard chemotherapy (capecitabine) can help people with advanced estrogen receptor-positive (ER+) breast cancer that no longer responds to CDK 4/6 inhibitors. About 297 participants will be randomly assigned to get either the combi…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Kristina A. Fanucci • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Smart dosing trial aims to outsmart metastatic breast cancer
Disease control Recruiting nowThis study tests a new way of giving the chemotherapy drug capecitabine to people with metastatic ER-positive, HER2-negative breast cancer. Instead of a fixed dose, the dose is adjusted based on how the tumor responds on scans and blood tests. The goal is to better control the ca…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 18, 2026 12:01 UTC
-
New trial matches breast cancer patients to smarter treatments using tumor markers
Disease control Recruiting nowThis study is for people with metastatic breast cancer (cancer that has spread). It aims to see if choosing treatments based on specific tumor markers (biomarkers) can help control the disease longer. About 700 participants will receive standard therapies matched to their biomark…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 18, 2026 11:59 UTC